Dr. Khan Discusses Sequencing Strategies in Advanced HCC

Gazala N. Khan, MD
Published: Friday, May 17, 2019



Gazala N. Khan, MD, medical oncologist, Henry Ford Health System, discusses sequencing strategies in advanced hepatocellular carcinoma (HCC).

Given the recent advances in this disease that have led to several FDA-approved agents in the frontline and second-line settings, sequencing is going to be a challenge, Khan says. However, data from the REFLECT study suggest that lenvatinib (Lenvima) is the preferred frontline agent after showing superior response rates and time to progression compared with sorafenib (Nexavar).

In terms of second-line therapy, there are many reasonable options like cabozantinib (Cabometyx) and ramucirumab (Cyramza). Nivolumab (Opdivo) may also be a suitable second-line option, contingent on more mature data. Until more data define the optimal sequence of these drugs, Khan says it should be decided by patient characteristics and preference.
SELECTED
LANGUAGE


Gazala N. Khan, MD, medical oncologist, Henry Ford Health System, discusses sequencing strategies in advanced hepatocellular carcinoma (HCC).

Given the recent advances in this disease that have led to several FDA-approved agents in the frontline and second-line settings, sequencing is going to be a challenge, Khan says. However, data from the REFLECT study suggest that lenvatinib (Lenvima) is the preferred frontline agent after showing superior response rates and time to progression compared with sorafenib (Nexavar).

In terms of second-line therapy, there are many reasonable options like cabozantinib (Cabometyx) and ramucirumab (Cyramza). Nivolumab (Opdivo) may also be a suitable second-line option, contingent on more mature data. Until more data define the optimal sequence of these drugs, Khan says it should be decided by patient characteristics and preference.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x